Why Should You Put Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) On Your Portfolio?

Currently, there are 1.12B common shares owned by the public and among those 1.12B shares have been available to trade.

The company’s stock has a 5-day price change of 2.62% and 34.00% over the past three months. TEVA shares are trading 35.15% year to date (YTD), with the 12-month market performance up to 61.07% higher. It has a 12-month low price of $7.09 and touched a high of $14.45 over the same period. TEVA has an average intraday trading volume of 10.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.62%, 9.74%, and 38.67% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) shares accounts for 52.47% of the company’s 1.12B shares outstanding.

It has a market capitalization of $15.82B and a beta (3y monthly) value of 1.05. The earnings-per-share (ttm) stands at -$0.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.23% over the week and 2.43% over the month.

Analysts forecast that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will achieve an EPS of $0.52 for the current quarter, $0.58 for the next quarter and $2.63 for 2025. The lowest estimate earnings-per-share for the quarter is $0.47 while analysts give the company a high EPS estimate of $0.57. Comparatively, EPS for the current quarter was $0.4 a year ago. Earnings per share for the fiscal year are expected to decrease by -6.11%, and 9.71% over the next financial year. EPS should shrink at an annualized rate of 1.60% over the next five years, compared to 26.63% over the past 5-year period.

Looking at the support for the TEVA, a number of firms have released research notes about the stock. JP Morgan stated their Neutral rating for the stock in a research note on March 08, 2024, with the firm’s price target at $14. Piper Sandler coverage for the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock in a research note released on February 12, 2024 offered a Overweight rating with a price target of $19. Jefferies was of a view on January 23, 2024 that the stock is Buy, while Piper Sandler gave the stock Neutral rating on January 03, 2024, issuing a price target of $8- $12. HSBC Securities on their part issued Buy rating on December 18, 2023.

Most Popular

Related Posts